- Growing Opportunities for Cmos and Cdmos.
- Emerging Markets.
Major Objectives of this Study:
# To define, describe, and forecast the global High Potency APIs Market on the basis of type, type of manufacturer, type of synthesis, therapeutic application, and region.
# To provide detailed information about factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).
# To strategically analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market.
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
# To forecast the size of the market segments of North America, Europe, Asia, and the Rest of the World (RoW).
# To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies.
# To track and analyze competitive developments such as agreements, partnerships, collaborations, and alliances; mergers and acquisitions; expansions; and R&D activities in the global market.
Expected Revenue Surge:
The global HPAPI market is expected to reach USD 26.84 Billion by 2023 from USD 16.49 Billion in 2017, at a CAGR 8.7%. The base year considered for the study is 2017 and the forecast period is from 2018 to 2023.
Download PDF Brochure @ High Potency APIs Market
Major Growth Boosting Factors:
The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine.
Target Audience for this Report:
# Manufacturers of HPAPI
# Distributors and suppliers of HPAPIs
# Potential investors in the HPAPI market
# Pharmaceutical companies
# Biotechnology companies
# Contract manufacturing organizations
# Life science research centers
# Healthcare payers
The HPAPIs market is fragmented, with the presence of several large as well as emerging players. Prominent players in the HPAPIs market include Pfizer (US), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva (Israel), Eli Lilly and Company (US), Merck (US), AbbVie (US), Mylan (US), and F. Hoffmann-La Roche (Switzerland). Players in this market are adopting various organic and inorganic strategies, such as agreements, collaborations, alliances, and partnerships; mergers and acquisitions; and expansions.
Request Sample Pages@ High Potency APIs Market
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.